Home » Topics » BioWorld Science

BioWorld Science
RSS

Preliminary data presented from phase I/II ASPIRO study of AT-132

Oct. 9, 2019

Selepressin does not improve vasopressor- and ventilator-free days in patients with septic shock

Oct. 9, 2019

Discovery of novel potent fully human FVIII mimetic BiAb, KY-1049

Oct. 9, 2019

New mouse model of diabetic cystopathy described

Oct. 9, 2019

Xoc Pharmaceuticals launches phase I study of XC101-D13H

Oct. 9, 2019

NGM reports promising interim results from ongoing phase II study of aldafermin in NASH

Oct. 9, 2019

An inclusive look at the microbiome

Oct. 9, 2019

ONL Therapeutics advances ONL-1204 into phase I study for retinal detachment

Oct. 8, 2019

Bavarian Nordic begins first-in-human study of MVA-BN-WEV for equine encephalitis virus

Oct. 8, 2019

Three win Nobel for hypoxia work

Oct. 8, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...